term or long term treatment with continuous ambulatory peritoneal dialysis. The small difference may be related to the number of transplant operations performed in patients who received short term treatment.
Complications after transplantation related to continuous ambulatory peritoneal dialysis were minimal. Only one episode of peritonitis was observed, which was easily treated with intraperitoneal antibiotics. Cramer et al reported the development of peritonitis after transplantation in one patient who received continuous ambulatory peritoneal dialysis who had never had an episode of peritonitis before transplantation, indicating a risk of activation of subclinical peritonitis in an immunosuppressed patient.9 This was not observed by us or others. 6 10 Eight of our 42 patients who had had at least four episodes of peritonitis before transplantation, and who could, therefore, be considered to be patients at high risk, had no apparent peritoneal infection after transplantation.
The routine maintenance of the indwelling Tenckhoff catheter after transplantation was not a problem. It was used by choice in four of 19 patients who required dialysis in the immediate postoperative period. Those catheters that were not removed at the time of transplantation were withdrawn after a mean of three months when the graft function was stable. The operation was uneventful, and in 15 patients it was performed at the same time as removal of the ureteric stent at cystoscopy.
In conclusion, continuous ambulatory peritoneal dialysis is not an impediment to successful renal transplantation. The risk of peritonitis after transplantation should be borne in mind in patients treated with continuous ambulatory peritoneal dialysis, and even in the absence of clinical signs we would advise routine sampling of peritoneal fluid for bacteriological study.
The Tenckhoff catheter can be used to perform dialysis in those who do not have immediate graft function. Short term treatment with continuous ambulatory peritoneal dialysis is an excellent mode of treatment as a "parking place" for patients awaiting renal transplantation, which does not take up places in renal units, allows patients home in a week or two, and has minimal capital costs.
Introduction
Although ovarian cancer is only the fourth most common cause of death from cancer in women, it is the major cause of death from a gynaecological malignancy in most developed countries.' Despite claims of effective treatment in many reports of clinical trials,2 statistics of survival do not indicate any substantial improvements in the management of the disease.4 5 The real yield of experimental treatments tested in randomised controlled trials is difficult to assess mainly because of the selection of patients and low quality of design and implementation of most of them, as has been recently documented.5 Poor compliance to key procedures, specifically understaging, is one factor causing the low impact of potentially effective treatments on cure and prolongation of survival. 6 In 1979 in Italy we started a monitoring programme aimed at evaluating the process of care in patients with different malig-nancies seen at institutions with varying degrees of organisation and skill. The findings have already been reported for cancer of the breast7 and lung.8 For ovarian cancer the study of the quality of care was extended to investigate its impact on the clinical outcome in terms of survival. The results are discussed here, also from the point of view of their possible implications in the planning of future clinical trials and ways of caring.
Patients and methods
Because the surveys of process and outcome had different goals and methodology they are described separately.
SURVEY OF PROCESS
This consisted of a retrospective chart audit of all patients admitted with the diagnosis of ovarian cancer to one of the 31 participating centres over two years . Explicit criteria defining norms of diagnostic and therapeutic care considered feasible and acceptable patients.
Better quality was found regarding surgical procedures. Although some techniques such as omentectomy, relevant for more accurate staging, had not entered general hospital practice, the quality of surgical management appeared to be generally acceptable: 160 (580w) patients received the standard type of management (reference should be made to the time at which patients were first diagnosed and treated), 76 (27 0 ) received a partial procedure, and for 41 (15°/) no information was available about surgical management. Of the 36 patients for whom laparotomy and biopsy were reported, 20 were aged over 70 or had inoperable disease at surgery, while for the remaining 16 no information useful for evaluating appropriateness of care was available.
In respect of medical treatment, 95 (52%) patients received a regimen that was acceptable by our criteria. Monochemotherapy with an alkylating agent was the form of treatment most widely used (70 patients (380')) even in advanced cases, while only 25 patients (14%) were treated with a more aggressive regimen. Almost half of the patients given chemotherapy (90 (48%)) received a poorly active regimen of single or multiple drugs (doxorubicin alone, cyclophosphamide, methotrexate, 5-fluorouracil (HEXA-CAF), or other types of drugs grouped under the category "others"). A third of the patients (100 (36%)) did not receive any medical treatment.
The follow up seemed to be particularly unsatisfactory: for 125 (46%) patients no information was given in the charts after periods of follow up varying from three to 24 months (table I) . No major differences in quality of care in the two groups of hospitals emerged in the proportions of patients still followed up at the end of the study, who were from the more specialised institutions (55°h v 25h X2= 238, p<0001). When items reflecting the quality of reporting of information in the clinical charts were considered, hospitals with oncology facilities fared better than those without. The proportion of patients with complete information on surgical and medical management was significantly higher in more specialised centres, 21% v 100°and 52% v 25%, respectively; X21 = 6.65, p < 001 and X'21 =16 91, p < 0001).
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68 (5) 55 (6) 44 (6) 35 (6) come for whom the stage of disease was evaluable. In agreement with the survey of process again no significant differences in quality of care emerged between centres. In the early stages (I and II) 25 out of 31 patients treated in specialised institutions and 21 out of 30 from non-specialised centres underwent a standard surgical procedure. In the advanced stages (III and IV) only nine out of 50 patients from specialised hospitals and seven out of 32 from institutions without oncology services underwent standard surgery and an acceptable chemotherapy regimen. Among acceptable chemotherapy regimens, multidrug regimens containing cisplatin were slightly more common in specialised centres, while monochemotherapy with an alkylating agent occurred more often in less specialised institutions. The duration of chemotherapy was comparable (median 4 5 and 4 1 months in more and less specialised hospitals, respectively). Figure  2 shows the survival of patients in the survey of outcome with results for the whole series and by groups of hospitals. Table III shows rates of survival at yearly intervals. At five years no difference was evident between patients treated in the two groups of hospitals (35%o in oncology centres v 360/ in those without oncological facilities; 21 log rank = 026). Similarly, no differences emerged when patients with earlier stages and those with more advanced disease were examined separately (X21 long rank = 0 10 and 1 14, respectively). Figure 3 shows that data worthy of confidence attract reliable, imitative, routine clinical practice. 10 Compliance to standard regimens must, therefore, be judged by completely different criteria, according to the type of disease and treatment. Far from being a failure poor compliance in cancer of the ovaries might in some instances, seen from the hard end point of the outcome, be considered to be a defensive reaction against a burden of intervention that appears unjustified. It should be clear that omitting some parts of a regimen does not automatically mean a better quality of life for the patient, such as fewer side effects, but simply the exposure to causally linked procedures, which could entail worse side effects without assuring minimal benefits. 1' 12 Improving the situation does not therefore rest in trying to educate general hospitals to adopt standards of research or let them play empirically with regimens because results would be the same. A more scientific and ethically sound application of the above results might be to establish a strategy of easily applicable regimens monitored in large scale trials whenever a new or tenable hypothesis is at hand. This could well be true for not only cancer of the ovaries but also similarly "resistant" situations. When no hard recommendations are at hand a positively sober, not just permissive, attitude should be enforced to minimise risks, false impressions, and waste of resources. Integrated periodical studies of quality of process and outcome seem to provide a promising tool for monitoring the real yield of delivered care specifically in cancer but also in all conditions where effective treatments are not the rule. Bronchoscopy was performed using a fully immersible Olympus BF10 fibreoptic bronchoscope; the operator wore sterile gown, gloves, mask, and goggles. Bronchoalveolar lavage, using 100-180 ml 0 9%0 saline in 20-50 ml aliquots, was followed by transbronchial biopsy (without fluoroscopic control) in the area of lung with maximum radiological abnormality (if present).
The bronchoscope was disinfected with 20, glutaraldehyde for three hours after use.
Cytological, virological, and bacteriological examination of lavage fluid was performed using Gram, Ziehl-Neelsen, and Gomori's methenamine silver nitrate stain. Transbronchial biopsy tissue was pressed on to a slide to make touch preparations for cytological studies; the remainder was placed in formol saline for histological examination and in viral transport medium for culture.
Pn carinii was identified in 16 patients (table)-by transbronchial biopsy in 15, by touch preparations in four, and by bronchoalveolar lavage in five. In four patients endobronchial Kaposi's sarcoma was seen; all four had cutaneous lesions. Infections with Mycobacterium tuberculosis, cytomegalovirus, Gram positive cocci (Streptococcus pneumoniae and Staphylococcus aureus), and Candida albicans were identified in 11 patients; multiple infections were present in three. Negative findings with a strong clinical diagnosis of Pn carznzi pneumonia and prompt response to high dose co-trimoxazole were classified as false negative.
Early mortality-that is, within one month of bronchoscopy-occurred in two patients with Pn carinii pneumonia, both of whom had concurrent cytomegalovirus infection; most patients (four out of five) with cytomegalovirus or candidal pneumonitis died within 28 days.
The procedure was well tolerated. Three patients developed pneumothoraces, one requiring drainage, and one patient bled 50 ml after biopsy, requiring topical adrenaline. 
